Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN- LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

NCT02840721 is registered in ClinicalTrials.gov with Telavant, Inc. as lead sponsor.

NCT NCT02840721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02840721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN- LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Lead sponsor
Telavant, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 26, 2016
Completion date
August 30, 2018
Enrollment
50 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative